Dr. Drew Moghanaki, chief of thoracic oncology in UCLA’s department of radiation oncology and a researcher at the UCLA Health Jonsson Comprehensive Cancer Center, has been named a 2025 fellow of the American Society for Radiation Oncology (ASTRO).
The recognition is awarded annually to physicians, physicists, and scientists in honor of their exceptional achievements and lasting contributions to the society, cancer research, education, patient care, and the field of radiation oncology, highlighting work that advances the critical role of radiation therapy in cancer treatment.
Moghanaki, a national leader in lung cancer care, is renowned for his expertise in high-precision, non-invasive radiation therapies, including stereotactic body radiation therapy (SBRT), intensity-modulated radiation therapy (IMRT), and magnetic resonance-guided radiation therapy (MRgRT). He leads multiple national research efforts, including the national VALOR clinical trial, where he is comparing outcomes for patients treated with SBRT versus surgery and providing critical evidence on non-invasive alternatives to traditional lung surgery.
“It’s truly an honor to be part of the 2025 class of ASTRO fellows,” Moghanaki said. “I join many outstanding physicians and scientists who dedicate their work every day to advancing radiation therapy and developing innovative treatment options for people diagnosed with lung cancer and other challenging cancers.”
Moghanaki will be recognized at ASTRO’s 67th Annual Meeting in San Francisco on Tuesday, September 30.
